O05 - Once-daily tiotropium in adolescents with symptomatic asthma despite inhaled corticosteroid treatment: a dose-ranging study
نویسندگان
چکیده
Methods This randomised, placebo-controlled, double-blind, incomplete crossover study (NCT01122680) evaluated the efficacy and safety of 5, 2.5 and 1.25 μg once-daily (evening) tiotropium (via Respimat Soft MistTM Inhaler) versus placebo in three 4-week treatment periods in adolescents (aged 12-17 years) with symptomatic asthma despite medium-dose ICS. The primary efficacy end point was change in peak forced expiratory volume in 1 second within 3 hours post-dose (peak FEV1(0-3h)) assessed as a response (difference from baseline). Secondary end points included trough FEV1, FEV1 area under the curve (AUC)(0-3h), peak expiratory flow (PEFam/pm) responses and Asthma Control Questionnaire (ACQ) score.
منابع مشابه
A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids
BACKGROUND A considerable number of children with asthma remain symptomatic despite treatment with inhaled corticosteroids, resulting in significant morbidity, reduced quality of life, increased healthcare costs and lost school days. The aim of our study was to assess the efficacy, safety and tolerability of once-daily tiotropium Respimat® 5 μg, 2.5 μg and 1.25 μg add-on to medium-dose inhaled ...
متن کاملTiotropium bromide in asthma patients: an alternative to inhaled long-acting beta-agonists?
SUMMARY Asthma affects an estimated 5.4 million people in the UK. 1 Many patients remain symptomatic despite regular inhaled therapies. Given the burden of asthma and the heterogeneity of patients, the role of new therapeutic options requires evaluation. Tiotropium bromide has a well-established role in the management of chronic obstructive pulmonary disease (COPD). This is the first comprehens...
متن کاملLong-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study
BACKGROUND This study assessed the long-term safety and efficacy of tiotropium Respimat, a long-acting inhaled anticholinergic bronchodilator, in asthma, added on to inhaled corticosteroids (ICS) with or without long-acting β2-agonist (LABA). METHODS 285 patients with symptomatic asthma, despite treatment with ICS±LABA, were randomised 2:2:1 to once-daily tiotropium 5 μg, tiotropium 2.5 μg or...
متن کاملTiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma
BACKGROUND Tiotropium, a once-daily long-acting anticholinergic bronchodilator, when administered via Respimat® SoftMist™ inhaler (tiotropium Respimat®) significantly reduces the risk of severe exacerbations and improves lung function in patients with severe persistent asthma that is not fully controlled despite using inhaled corticosteroids (ICS) and long-acting β2-agonists. To further explore...
متن کاملEfficacy and Safety of Tiotropium in Children and Adolescents
Asthma is one of the most common chronic diseases in children, with a high proportion of patients demonstrating poor control despite the availability of disease management guidelines. Global Initiative for Asthma guidelines include tiotropium as an add-on therapy option at Steps 4 and 5 in patients aged ≥ 12 years with a history of exacerbations, and tiotropium delivered via the Respimat® Soft ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 4 شماره
صفحات -
تاریخ انتشار 2014